Qiagen Expands Digital PCR Portfolio for Gene Expression Analysis
Qiagen N.V. has expanded its QIAcuity portfolio with new reagents for gene expression analysis. The expansion aims to drive the adoption of digital PCR in research and biopharmaceutical sectors.
Biotechnology company Qiagen N.V. announced an expansion of its digital PCR (polymerase chain reaction) offerings with new reagents for its QIAcuity platform. These new kits are specifically designed for gene expression analysis applications.
The company is introducing two new reagent kits: QIAcuity GenXplore for RNA analysis and QIAcuity GenXplore for DNA analysis. These are intended to accelerate and simplify genome-wide gene expression studies.
Qiagen states that the new solutions provide high-resolution analysis and data accuracy, which are critical for drug discovery and biological research. This move is part of the company's strategy to enhance its presence in the digital PCR market and promote wider use of the technology across scientific disciplines.
Digital PCR offers highly precise quantification of nucleic acids and is increasingly utilized in fields such as cancer research, infectious disease diagnostics, and new drug development. Qiagen aims to make this powerful technique more accessible to a broader range of researchers and organizations.